Literature DB >> 23126353

Renal denervation in a hypertensive patient with end-stage renal disease and small arteries: a direction for future research.

Christian Ott1, Axel Schmid, Tilmann Ditting, Paul A Sobotka, Roland Veelken, Michael Uder, Roland E Schmieder.   

Abstract

Sympathetic overactivity plays a crucial pathogenetic role in the maintenance and aggravation of arterial hypertension in patients with end-stage renal disease (ESRD). Renal denervation has been shown to be effective and safe in reducing blood pressure (BP) in patients with treatment-resistant hypertension; however, there are only case reports in hypertensive patients with ESRD and data are lacking about possibility of renal denervation in small renal arteries. A woman with uncontrolled treatment-resistant hypertension on chronic hemodialysis underwent bilateral native kidney, catheter-based renal denervation. Both native renal arteries were <4 mm. After 6 months without any change of antihypertensive medication or hemodialysis parameters, the authors observed a remarkable BP reduction of 38/30 mm Hg (from baseline 172/100 mm Hg to 134/70 mm Hg) as evaluated by 24-hour ambulatory BP monitoring. The authors report that renal denervation seems to be effective in controlling hypertension in patients with ESRD, even in cases of small renal arteries.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 23126353      PMCID: PMC8108926          DOI: 10.1111/jch.12017

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  10 in total

1.  Tonic postganglionic sympathetic inhibition induced by afferent renal nerves?

Authors:  Tilmann Ditting; Wolfgang Freisinger; Kirsten Siegel; Christian Fiedler; Lisa Small; Winfried Neuhuber; Sonja Heinlein; Peter W Reeh; Roland E Schmieder; Roland Veelken
Journal:  Hypertension       Date:  2012-01-03       Impact factor: 10.190

2.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.

Authors:  Murray D Esler; Henry Krum; Paul A Sobotka; Markus P Schlaich; Roland E Schmieder; Michael Böhm
Journal:  Lancet       Date:  2010-11-17       Impact factor: 79.321

Review 3.  Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept.

Authors:  Markus P Schlaich; Paul A Sobotka; Henry Krum; Robert Whitbourn; Anthony Walton; Murray D Esler
Journal:  Hypertension       Date:  2009-10-12       Impact factor: 10.190

4.  Catheter-based radiofrequency ablation therapy of the renal sympathetic-nerve system for drug resistant hypertension in a patient with end-stage renal disease.

Authors:  D Prochnau; A Lauten; M Busch; H Kuehnert; H R Figulla; R Surber
Journal:  Int J Cardiol       Date:  2011-06-01       Impact factor: 4.164

5.  Sympathetic nerve activity in end-stage renal disease.

Authors:  Martin Hausberg; Markus Kosch; Patrick Harmelink; Michael Barenbrock; Helge Hohage; Klaus Kisters; Karl Heinz Dietl; Karl Heinz Rahn
Journal:  Circulation       Date:  2002-10-08       Impact factor: 29.690

6.  Renal sympathetic nerve ablation for the treatment of difficult-to-control or refractory hypertension in a haemodialysis patient.

Authors:  Nicola Di Daniele; Marianna De Francesco; Leano Violo; Alessio Spinelli; Giovanni Simonetti
Journal:  Nephrol Dial Transplant       Date:  2012-04       Impact factor: 5.992

7.  Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease.

Authors:  Carmine Zoccali; Francesca Mallamaci; Saverio Parlongo; Sebastiano Cutrupi; Francesco Antonio Benedetto; Giovanni Tripepi; Graziella Bonanno; Francesco Rapisarda; Pasquale Fatuzzo; Giuseppe Seminara; Alessandro Cataliotti; Benedetta Stancanelli; Lorenzo Salvatore Malatino; Alessandro Cateliotti
Journal:  Circulation       Date:  2002-03-19       Impact factor: 29.690

8.  Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation.

Authors:  Kazi Rafiq; Takahisa Noma; Yoshihide Fujisawa; Yasuhiro Ishihara; Yoshie Arai; A H M Nurun Nabi; Fumiaki Suzuki; Yukiko Nagai; Daisuke Nakano; Hirofumi Hitomi; Kento Kitada; Maki Urushihara; Hiroyuki Kobori; Masakazu Kohno; Akira Nishiyama
Journal:  Circulation       Date:  2012-02-10       Impact factor: 29.690

9.  Renal afferent denervation prevents hypertension in rats with chronic renal failure.

Authors:  V M Campese; E Kogosov
Journal:  Hypertension       Date:  1995-04       Impact factor: 10.190

10.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.

Authors:  Henry Krum; Markus Schlaich; Rob Whitbourn; Paul A Sobotka; Jerzy Sadowski; Krzysztof Bartus; Boguslaw Kapelak; Anthony Walton; Horst Sievert; Suku Thambar; William T Abraham; Murray Esler
Journal:  Lancet       Date:  2009-03-28       Impact factor: 79.321

  10 in total
  11 in total

Review 1.  Sympathetic hyperactivity in chronic kidney disease: pathophysiology and (new) treatment options.

Authors:  Eva E Vink; Rosa L de Jager; Peter J Blankestijn
Journal:  Curr Hypertens Rep       Date:  2013-04       Impact factor: 5.369

2.  Renal sympathetic denervation in resistant hypertension.

Authors:  Mário Santos; Henrique Carvalho
Journal:  World J Cardiol       Date:  2013-04-26

Review 3.  Antihypertensive Agents in the Dialysis Patient.

Authors:  Michelle A Fravel; Elizabeth Bald; Mony Fraer
Journal:  Curr Hypertens Rep       Date:  2019-01-18       Impact factor: 5.369

Review 4.  Patient Selection for Renal Denervation in Hypertensive Patients: What Makes a Good Candidate?

Authors:  Sheran Li; Jacqueline K Phillips
Journal:  Vasc Health Risk Manag       Date:  2022-05-13

Review 5.  The sympathetic nervous system in chronic kidney disease.

Authors:  Sebastian Ewen; Christian Ukena; Dominik Linz; Roland E Schmieder; Michael Böhm; Felix Mahfoud
Journal:  Curr Hypertens Rep       Date:  2013-08       Impact factor: 5.369

6.  Treatment of atrial fibrillation in patients with enhanced sympathetic tone by pulmonary vein isolation or pulmonary vein isolation and renal artery denervation: clinical background and study design : The ASAF trial: ablation of sympathetic atrial fibrillation.

Authors:  Mark R de Jong; Annemiek F Hoogerwaard; Ahmet Adiyaman; Jaap Jan J Smit; Anand R Ramdat Misier; Jan-Evert Heeg; Boudewijn A A M van Hasselt; Isabelle C Van Gelder; Harry J G M Crijns; Ignacio Fernández Lozano; Jorge E Toquero Ramos; F Javier Alzueta; Borja Ibañez; José M Rubio; Fernando Arribas; José M Porres Aracama; Josep Brugada; Lluís Mont; Arif Elvan
Journal:  Clin Res Cardiol       Date:  2018-02-27       Impact factor: 5.460

Review 7.  Exploring issues in difficult-to-treat hypertension.

Authors:  Michael A Weber
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-10-30       Impact factor: 3.738

8.  Endovascular renal denervation: a novel sympatholytic with relevance to chronic kidney disease.

Authors:  Neil A Hoye; James C Baldi; Tracey L Putt; John B Schollum; Gerard T Wilkins; Robert J Walker
Journal:  Clin Kidney J       Date:  2013-11-08

Review 9.  Obesity-related metabolic syndrome: mechanisms of sympathetic overactivity.

Authors:  Maria Paola Canale; Simone Manca di Villahermosa; Giuliana Martino; Valentina Rovella; Annalisa Noce; Antonino De Lorenzo; Nicola Di Daniele
Journal:  Int J Endocrinol       Date:  2013-10-31       Impact factor: 3.257

10.  Endovascular Renal Denervation in End-Stage Kidney Disease Patients: Cardiovascular Protection-A Proof-of-Concept Study.

Authors:  Neil A Hoye; Luke C Wilson; Gerard T Wilkins; David L Jardine; Tracey L Putt; Ari Samaranayaka; John B W Schollum; Robert J Walker
Journal:  Kidney Int Rep       Date:  2017-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.